Solvias Appoints New CEO - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Solvias Appoints New CEO



Solvias, a pharmaceutical service provider, has appointed Karen Huebscher to succeed Hansjörg Walther as CEO. Walther will retire and hand over operational management of the company to Huebscher, effective March 1, 2014. In 2000, Huebscher became head of investor relations at Novartis. In 2006, she joined the global executive leadership team of the Vaccines and Diagnostics division, headquartered in the United States.

As a member of the Executive Committee, Huebscher was responsible for business development (in-and out licensing) and M&A. After her return from the US, Huebscher took on responsibility for vaccine marketing in Europe and became site head for the Vaccines & Diagnostics division in Basel. In 2012, she founded Fibula Medical and was also appointed to the Board of Directors of Tecan. Huebscher has been a member of the Board of Directors of Solvias since 2013. Walther will retain his seat on the Board of Directors.

Source: Solvias

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here